On Tuesday, Cisco Systems, Inc.(NASDAQ:CSCO)’s shares declined -1.57% to $25.14.
Barilla Group, the makers of Barilla brand pastas and sauces, is embracing the Internet of Everything (IoE) to provide consumers the ability to trace the entire chain of production for the ingredients in their food, from where it was grown to how it arrived on the store shelf. Barilla worked with Cisco (CSCO), Penelope S.p.A. and NTT DATA to implement a new technology platform called Safety for Food (S4F). Powered by the software ValueGo®, the platform enables consumers to scan a QR code on the back of limited edition Farfalle Pasta and Tomato and Basil Sauce packages to easily access a website that tells the story of the specific production batch, through a detailed analysis of all major phases of the supply chain. Consumers can find the limited edition Barilla pasta and sauce packages at the Coop Supermarket of the Future, part of the Future Food District at EXPO 2015 in Milan.
ValueGo®, developed by Penelope S.p.A., is the core system of the Safety for Food project, with specific agri-food vertical features for compliance checking, tracking and tracing of all food information along the entire supply chain and for building a ‘digital passport’ for food products.
Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking products and services related to the communications and information technology industry worldwide. It provides switching products, counting fixed-configuration and modular switches, and storage products that provide connectivity to end users, operate stations, IP phones, wireless access points, and servers; and next-generation network routing products that interconnect public and private wireline and mobile netoperates for mobile, data, voice, and video applications.
Cypress Semiconductor Corporation (NASDAQ:CY)’s shares dropped -2.36% to $9.11.
Cypress Semiconductor Corp. (CY) introduced a new automotive capacitive touchscreen controller family that enables screen sizes up to 15-inches with industry-leading performance in harsh automotive environments. The new Automotive TrueTouch® CYAT8168X controller uses Cypress’s proprietary AutoArmor™ technology for robust immunity to the strong electromagnetic interference (EMI) emissions found in cars, buses and trucks. The controller delivers a flawless user experience even with water droplets, condensation or sweat on the touchscreen. Additionally, the controllers provide industry-leading tracking of fingers in gloves, allowing drivers to operate the touchscreen without having to take off their gloves.
Cypress AutoArmor meets car manufacturers’ most challenging electromagnetic compatibility (EMC) requirements for chip-level emissions (IEC 61967), conducted (IEC 62132) and radiated (ISO 11452) immunity, in addition to for system-level (CISPR 25) specifications. AutoArmor uses automatic frequency hopping to prevent false touches caused by EMI from other electronic systems, and it uses TX frequency spreading to reduce electromagnetic emissions by up to 30%. In addition to AutoArmor, the Automotive TrueTouch CYAT8168X controller comprises up to 88 I/Os with a host processor interface through I2C or SPI, which assist improve touchscreen responsiveness.
Cypress Semiconductor Corporation provides mixed-signal programmable solutions, semiconductor memories, and integrated semiconductor solutions worldwide. The company’s Memory Products division designs and manufactures static random access memory (SRAM) products and nonvolatile RAMs used to store and retrieve data in networking, wireless infrastructure and handsets, computation, consumer, automotive, industrial, and other electronic systems; and general-purpose programmable clocks.
At the end of Tuesday’s trade, ISIS Pharmaceuticals, Inc.(NASDAQ:ISIS)‘s shares dipped -3.92% to $48.23.
Isis Pharmaceuticals, Inc. (ISIS) declared that its partnership with AstraZeneca to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. AstraZeneca will pay Isis a $65 million up-front payment. Isis is eligible to receive development and regulatory milestones for each program that AstraZeneca advances to clinical development. Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each program.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
Advaxis, Inc.(NASDAQ:ADXS), ended its Tuesday’s trading session with 0.81% gain, and closed at $16.12.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and the Gynecologic Oncology Group (GOG, now part of NRG Oncology), declared clinical data from Stage 1 of an ongoing two-stage Phase 2 study (GOG-0265) of Advaxis’s lead Lm Technology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) who have progressed on at least one prior line of systemic therapy. The Stage 1 data showed that treatment with axalimogene filolisbac resulted in a 38.5 percent 12-month overall survival rate in 26 patients.
Evaluation of safety data showed that Grade 1 or 2 adverse events occurred in 19 out of 26 patients (73 percent), with fatigue, chills and fever being the most common. Four patients (15 percent) experienced a Grade 3 adverse event (hypotension and cytokine release syndrome) and one patient (4 percent) experienced a Grade 4 adverse event (lung infection and sepsis). The results were presented at the American Gynecological & Obstetrical Society (AGOS) annual meeting in Half Moon Bay, Calif. by Tom Herzog, M.D., Clinical Director at the University of Cincinnati Cancer Institute.
Evaluation of safety data showed that Grade 1 or 2 adverse events occurred in 19 out of 26 patients (73 percent), with fatigue, chills and fever being the most common. Four patients (15 percent) practiced a Grade 3 adverse event (hypotension and cytokine release syndrome) and one patient (4 percent) practiced a Grade 4 adverse event (lung infection and sepsis). The results were presented at the American Gynecological & Obstetrical Society (AGOS) annual meeting in Half Moon Bay, Calif. by Tom Herzog, M.D., Clinical Director at the University of Cincinnati Cancer Institute.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
